Who
Sanofi
10% owner
Company insider
Files Form 4 as: 10% owner, Latigo Biotherapeutics; 10% owner, Attovia Therapeutics; 10% owner, Translate Bio; 10% owner, Icosavax; 10% owner, Inozyme Pharma; 10% owner, Regeneron Pharmaceuticals; 10% owner, Fulcrum Therapeutics; 10% owner, MyoKardia.
In numbers
- Trades disclosed
- 602
- Buys
- 78
- Sells
- 8
- Bought
- $10.1B
- Sold
- $12.1B
- Companies
- 14
- Companies where not an officer
- 14
- First trade
- 31 Dec 2007
- Last trade
- 10 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 12 Aug 2026 | LTGO Latigo BiotherapeuticsBiotechnology | SEC FORM 4 Code C | —494,800 | filing |
| 10 Aug 2026filed 12 Aug 2026 | LTGO Latigo BiotherapeuticsBiotechnology | SEC FORM 4 Code C | —177,978 | filing |
| 10 Aug 2026filed 12 Aug 2026 | LTGO Latigo Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —494,800 | filing |
| 10 Aug 2026filed 12 Aug 2026 | LTGO Latigo Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —494,800 | filing |
| 10 Aug 2026filed 12 Aug 2026 | LTGO Latigo Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —177,978 | filing |
| 10 Aug 2026filed 12 Aug 2026 | LTGO Latigo Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —177,978 | filing |
| 10 Aug 2026filed 12 Aug 2026 | LTGO Latigo BiotherapeuticsBiotechnology | SEC FORM 4 Code C | —494,800 | filing |
| 10 Aug 2026filed 12 Aug 2026 | LTGO Latigo BiotherapeuticsBiotechnology | SEC FORM 4 Code C | —177,978 | filing |
| 6 Aug 2026filed 7 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Code C | —782,855 | filing |
| 6 Aug 2026filed 7 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Bought | $5.1M300,000 at $17.00 | filing |
| 6 Aug 2026filed 7 Aug 2026 | ATTO Attovia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —782,855 | filing |
| 6 Aug 2026filed 7 Aug 2026 | ATTO Attovia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —782,855 | filing |
| 6 Aug 2026filed 7 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Code C | —782,855 | filing |
| 6 Aug 2026filed 7 Aug 2026 | ATTO Attovia TherapeuticsBiotechnology | SEC FORM 4 Bought | $5.1M300,000 at $17.00 | filing |
| 14 Sep 2021filed 14 Sep 2021 | Translate Bio | SEC FORM 4 Bought | $2.0B51,467,612 at $38.00 | filing |
| 14 Sep 2021filed 14 Sep 2021 | Translate Bio | SEC FORM 4 Bought | $779.6M20,515,985 at $38.00 | filing |
| 2 Aug 2021filed 2 Aug 2021 | Icosavax | SEC FORM 4 Code C | —3,088,502 at $0.00 | filing |
| 2 Aug 2021filed 2 Aug 2021 | Icosavax | SEC FORM 4 Bought | $1.0M66,667 at $15.00 | filing |
| 2 Aug 2021filed 2 Aug 2021 | Icosavaxoption or derivative | SEC FORM 4 Code C | —12,480,498 | filing |
| 2 Aug 2021filed 2 Aug 2021 | Icosavaxoption or derivative | SEC FORM 4 Code C | —354,393 | filing |
The newest 500 lines are listed; the numbers count every line.
News
No headline names them, or the companies they trade most, lately.